Skip to main content

REVIEW article

Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1379986
This article is part of the Research Topic Radioresistance in Breast Cancer View all 6 articles

Innovative Therapeutic Strategies to Overcome Radioresistance in Breast Cancer

Provisionally accepted
Christoph R. Arnold Christoph R. Arnold 1*Julian Mangesius Julian Mangesius 2Ute Ganswindt Ute Ganswindt 2Hendrik A. Wolff Hendrik A. Wolff 1
  • 1 Department of Radiology, Nuclear Medicine, and Radiotherapy, Radiology Munich, Munich, Germany, Munich, Germany
  • 2 Department of Radiation-Oncology, Medical University of Innsbruck, Innsbruck, Austria, Innsbruck, Austria

The final, formatted version of the article will be published soon.

    Despite a comparatively favorable prognosis relative to other malignancies, breast cancer continues to significantly impact women's health globally, partly due to its high incidence rate. A critical factor in treatment failure is radiation resistance – the capacity of tumor cells to withstand high doses of ionizing radiation. Advancements in understanding the cellular and molecular mechanisms underlying radioresistance, coupled with enhanced characterization of radioresistant cell clones, are paving the way for the development of novel treatment modalities that hold potential for future clinical application. In the context of combating radioresistance in breast cancer, potential targets of interest include long non-coding RNAs (lncRNAs), micro RNAs (miRNAs), and their associated signaling pathways, along with other signal transduction routes amenable to pharmacological intervention. Furthermore, technical, and methodological innovations, such as the integration of hyperthermia or nanoparticles with radiotherapy, have the potential to enhance treatment responses in patients with radioresistant breast cancer. This review endeavors to provide a comprehensive survey of the current scientific landscape, focusing on novel therapeutic advancements specifically addressing radioresistant breast cancer.

    Keywords: radioresistance, breast cancer, lncRNA, miRNA, hyperthermia, Nanoparticles, Radioimmunotherapy, Radiotherapy

    Received: 31 Jan 2024; Accepted: 10 May 2024.

    Copyright: © 2024 Arnold, Mangesius, Ganswindt and Wolff. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Christoph R. Arnold, Department of Radiology, Nuclear Medicine, and Radiotherapy, Radiology Munich, Munich, Germany, Munich, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.